AG-1557 hydrochloride

CAS No. ——

AG-1557 hydrochloride ( —— )

Catalog No. M19479 CAS No. ——

AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 49 Get Quote
10MG 78 Get Quote
25MG 155 Get Quote
50MG 286 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AG-1557 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
  • Description
    AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    hERG|EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    443.66
  • Molecular Formula
    C16H15ClIN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    Cl.COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Joshi A. Gadhwal M. and Joshi U.J. Indentification of potential novel EGFR inhibitors using a combination of pharmacophore and docking methods Int. J. Pharm. Pharmaceut. Sci. 7(6) (2015).
molnova catalog
related products
  • FRAX1036

    FRAX-1036 is a effective and selective PAK1 inhibitor.

  • EAI001

    EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.EAI001 can be used in cancer research.

  • SKLB 1028

    SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.